PT3339294T - Derivado de quinolona, sal farmaceuticamente aceitável ou estereoisómero do mesmo como inibidor de axl - Google Patents

Derivado de quinolona, sal farmaceuticamente aceitável ou estereoisómero do mesmo como inibidor de axl

Info

Publication number
PT3339294T
PT3339294T PT168366615T PT16836661T PT3339294T PT 3339294 T PT3339294 T PT 3339294T PT 168366615 T PT168366615 T PT 168366615T PT 16836661 T PT16836661 T PT 16836661T PT 3339294 T PT3339294 T PT 3339294T
Authority
PT
Portugal
Prior art keywords
stereoisomer
acceptable salt
pharmaceutical
pharmaceutical composition
quinolone derivative
Prior art date
Application number
PT168366615T
Other languages
English (en)
Original Assignee
Shanghai Inst Materia Medica Cas
Univ Jinan
Shanghai Haihe Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Inst Materia Medica Cas, Univ Jinan, Shanghai Haihe Pharmaceutical Co Ltd filed Critical Shanghai Inst Materia Medica Cas
Publication of PT3339294T publication Critical patent/PT3339294T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PT168366615T 2015-08-18 2016-08-18 Derivado de quinolona, sal farmaceuticamente aceitável ou estereoisómero do mesmo como inibidor de axl PT3339294T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510509618.5A CN106467541B (zh) 2015-08-18 2015-08-18 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用

Publications (1)

Publication Number Publication Date
PT3339294T true PT3339294T (pt) 2021-05-24

Family

ID=58050839

Family Applications (1)

Application Number Title Priority Date Filing Date
PT168366615T PT3339294T (pt) 2015-08-18 2016-08-18 Derivado de quinolona, sal farmaceuticamente aceitável ou estereoisómero do mesmo como inibidor de axl

Country Status (11)

Country Link
US (1) US10683278B2 (pt)
EP (1) EP3339294B1 (pt)
JP (1) JP6530857B2 (pt)
KR (1) KR102237707B1 (pt)
CN (2) CN106467541B (pt)
AU (1) AU2016309833B2 (pt)
DK (1) DK3339294T3 (pt)
ES (1) ES2873515T3 (pt)
IL (1) IL257481B (pt)
PT (1) PT3339294T (pt)
WO (1) WO2017028797A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107151240A (zh) * 2016-03-04 2017-09-12 中国科学院上海药物研究所 一类多取代喹诺酮类化合物及其制备方法和用途
CN107383016A (zh) * 2017-04-14 2017-11-24 江西科技师范大学 含杂芳基酰胺结构的吡咯并嘧啶化合物的制备及应用
JP7156287B2 (ja) 2017-08-23 2022-10-19 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含むがん治療剤
CN109422726B (zh) * 2017-09-04 2022-10-28 华东理工大学 CD47/SIRPα的阻断剂及其应用
WO2019074116A1 (ja) 2017-10-13 2019-04-18 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
CN107573340B (zh) * 2017-10-23 2020-11-24 江西科技师范大学 2-氨甲酰基-4-芳杂吡啶类化合物的制备及应用
CN110041316B (zh) * 2018-01-17 2022-04-19 药捷安康(南京)科技股份有限公司 Tam家族激酶/和csf1r激酶抑制剂及其用途
WO2019184918A1 (zh) * 2018-03-27 2019-10-03 暨南大学 3-氨基吡唑类化合物及其应用
IL277671B2 (en) * 2018-03-30 2024-03-01 Haihe Biopharma Co Ltd Quinoline (QUINOLINE) and quinazoline (QUINAZOLINE) compounds and their applications
CN108948014A (zh) * 2018-08-24 2018-12-07 江西科技师范大学 1-芳基-4-氧基-1,4-二氢喹啉结构的吡啶并杂环类化合物的制备及应用
CA3109891A1 (en) * 2018-08-24 2020-02-27 Nanjing Transthera Biosciences Co., Ltd. Quinoline derivative inhibitor: tam, ntrk, and csf1r kinases
CN111233661B (zh) * 2018-11-29 2023-03-31 暨南大学 靶向泛素化降解ERRα蛋白的化合物及其药用组合物和应用
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
EP3982965A4 (en) * 2019-06-12 2023-01-25 Praxis Biotech LLC INTEGRATED STRESS RESPONSE PATHWAY MODULATORS
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CN110974968B (zh) * 2019-12-11 2021-03-26 中山万远新药研发有限公司 含有喹诺酮类化合物的组合物及其用途
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN113372267B (zh) * 2020-03-10 2024-05-24 鲁南制药集团股份有限公司 一种c-Met激酶抑制剂
CN112939942B (zh) * 2020-12-24 2023-11-07 聊城大学 含喹啉结构的杂环酯类化合物及其制备方法与应用
CN115232118B (zh) * 2021-04-23 2024-07-19 中国药科大学 蛋白激酶抑制活性小分子及其衍生物、制备方法、药物组合物和应用
CN113278010A (zh) * 2021-06-01 2021-08-20 中国科学院上海有机化学研究所 一类蛋白激酶降解剂及其用途
CN115703737B (zh) * 2021-08-06 2024-09-24 暨南大学 一类羟基吡啶酮类化合物及其作为克服细菌生物膜耐药的抗生素增敏剂的应用
WO2023078252A1 (en) 2021-11-02 2023-05-11 Flare Therapeutics Inc. Pparg inverse agonists and uses thereof
CN114605391B (zh) * 2022-02-21 2024-01-26 广州六顺生物科技股份有限公司 喹喔啉类衍生物及其制备方法和应用
TW202413367A (zh) * 2022-08-19 2024-04-01 財團法人國家衛生研究院 Ｔａｍ受體抑制劑

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5525612B2 (pt) 1974-04-30 1980-07-07
US8354427B2 (en) * 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
PT1940844E (pt) * 2005-10-28 2010-01-06 Scripps Research Inst Compostos e composições como inibidores de proteína-quinase
RU2008127486A (ru) * 2005-12-08 2010-01-20 Милленниум Фармасьютикалз, Инк. (Us) Бициклические соединения с ингибиторной активностью в отношении киназы
UY31800A (es) * 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
JP2011063516A (ja) * 2009-09-15 2011-03-31 Daiichi Sankyo Co Ltd アミド誘導体
JP5525612B2 (ja) 2010-07-23 2014-06-18 国立大学法人 東京大学 含窒素複素環誘導体
EP2423208A1 (en) * 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors
AU2012339640B2 (en) * 2011-11-14 2017-01-05 Ignyta, Inc. Uracil derivatives as AXL and c-MET kinase inhibitors
CN102643268B (zh) 2011-12-30 2014-05-21 沈阳药科大学 喹啉类及噌啉类化合物及其应用
US8975282B2 (en) * 2012-07-28 2015-03-10 Sunshine Lake Pharma Co., Ltd. Substituted pyrazolone compounds and methods of use
MX2015001424A (es) * 2012-07-28 2016-03-09 Calitor Sciences Llc Compuestos pirazolona sustituidos y metodos de uso.
TWI649308B (zh) * 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
JP2016527274A (ja) * 2013-08-02 2016-09-08 イグナイタ インコーポレイテッド ＡＸＬ／ｃＭＥＴ阻害剤を単独または他の薬剤と組み合わせて用いて各種がんを治療する方法
SG11201605207PA (en) * 2013-12-26 2016-07-28 Ignyta Inc Pyrazolo[1,5-a]pyridine derivatives and methods of their use
WO2015164161A1 (en) 2014-04-22 2015-10-29 Calitor Sciences, Llc Bicylcic pyrazolone compounds and methods of use

Also Published As

Publication number Publication date
AU2016309833A1 (en) 2018-03-08
ES2873515T3 (es) 2021-11-03
KR102237707B1 (ko) 2021-04-08
CN108473434B (zh) 2021-11-23
WO2017028797A1 (zh) 2017-02-23
DK3339294T3 (da) 2021-07-12
EP3339294A1 (en) 2018-06-27
US10683278B2 (en) 2020-06-16
CN106467541A (zh) 2017-03-01
IL257481B (en) 2021-06-30
KR20180052640A (ko) 2018-05-18
CN108473434A (zh) 2018-08-31
CN106467541B (zh) 2019-04-05
US20180265496A1 (en) 2018-09-20
JP6530857B2 (ja) 2019-06-12
IL257481A (en) 2018-04-30
AU2016309833B2 (en) 2019-05-23
EP3339294B1 (en) 2021-04-14
JP2018528195A (ja) 2018-09-27
EP3339294A4 (en) 2019-02-20

Similar Documents

Publication Publication Date Title
PT3339294T (pt) Derivado de quinolona, sal farmaceuticamente aceitável ou estereoisómero do mesmo como inibidor de axl
HK1243999A1 (zh) 新型3-吲哚取代的衍生物、藥物組合物及使用方法
IL254714A0 (en) History of quinoline and pharmaceutical preparations containing them
HK1231377A1 (zh) 包含喹啉衍生物或其鹽的藥物組合物及其製備方法
IL269061A (en) A pharmaceutical preparation containing Selexifag
IL271986B1 (en) pharmaceutical preparation
EP3454899C0 (en) PHARMACEUTICAL COMPOSITION
GB201712159D0 (en) Pharmaceutical composition
HK1254573A1 (zh) 包含苯基氨基嘧啶衍生物的藥物組合物
PT3202759T (pt) Derivado de alfa-aminoamida e composição farmacêutica contendo o mesmo
IL263040A (en) Pharmaceutical composition comprising eteplirsen
PL3313370T3 (pl) Okulistyczna kompozycja farmaceutyczna
GB201521462D0 (en) Pharmaceutical composition
GB201719447D0 (en) Pharmaceutical composition
IL272419A (en) Pharmaceutical composition
EP3190129A4 (en) Centrally-acting peptide derivative, and pharmaceutical composition
GB201615917D0 (en) Pharmaceutical composition
EP3727485C0 (en) PHARMACEUTICAL COMPOSITION
GB201515310D0 (en) Pharmaceutical composition
GB201520862D0 (en) Pharmaceutical composition
GB201615914D0 (en) Pharmaceutical composition
GB201615910D0 (en) Pharmaceutical composition
HK1243358B (zh) 一種含有喹啉衍生物或其鹽的藥物組合物
HUE057830T2 (hu) Famitinib tartalmú gyógyszerkészítmény
GB201616088D0 (en) Pharmaceutical composition